In contrast, βCD-PRX treatment markedly inhibited the increase in the free cholesterol content of the CD11c-positive macrophages (localizing to CLS) from NASH livers (P < 0.01, Fig. 4 E). The gene discussed is ITGAX; the disease is metabolic dysfunction-associated steatohepatitis.